Psychological Distress in Patients Treated for Renal Cell Carcinoma: A Systematic Literature Review

Vartolomei, Liliana; Schmidinger, Manuela; Vartolomei, Mihai Dorin; Shariat, Shahrokh F.

doi:10.3390/jcm11216383

Cited by 4 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results support the role of inflammation in depression associated with malignancy and are the first to characterize this relationship in RCC. [3,4,7,32] Importantly, our results also demonstrated that patients with elevated CRP experienced a 3.53 increased odds of reporting clinically significant improvement postnephrectomy. RCC is unique in being one of the few cancers where CRP can be expressed directly by the tumor and surrounding kidney tissue.…”

Section: Discussionsupporting

confidence: 60%

“…[ [3][4][5] The reported level of depression in kidney cancer is greater than the pooled prevalence in various cancer subtypes, reaching as high as 19.7% with up to 77.6% of patients with nonmetastatic RCC experiencing depressive symptoms. [6,7] Cancer-related depression is associated with elevated mortality, increased medical nonadherence, and higher treatment costs in various malignancy subtypes including kidney, lung, breast, and brain cancers. [8][9][10] Over the past few decades, various studies suggest that inflammatory pathways may play a key role in the pathophysiology of depression.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The association of C-reactive protein with major depressive symptoms in nonmetastatic renal cell carcinoma

Nicaise,

Schmeusser,

Biermann

et al. 2023

Journal of Psychosocial Oncology Research &Amp; Practice

View full text Add to dashboard Cite

Introduction and Objective: Patients with kidney cancer experience higher rates of depression compared with other cancer subtypes. Inflammation has been shown to contribute to depression associated with malignancy. Here, we assess the association between preoperative C-reactive protein (CRP) and major depression, as screened by the eight-item Patient Health Questionnaire (PHQ-8) depression scale, in patients undergoing nephrectomy for nonmetastatic renal cell carcinoma (RCC). Methods: Retrospective review of prospectively administered PHQ-8 surveys in patients who underwent nephrectomy for nonmetastatic RCC was conducted. Patients with available PHQ-8 within 180 days before and after surgery were included. The association of major depressive symptoms on preoperative PHQ-8 and clinical improvement on postoperative survey with patient/tumor characteristics and CRP levels was determined by the generalized chi-square test for categorical variables and analysis of variance for continuous variables. Multivariable logistic regression was used to analyze variables associated with major depression on PHQ-8 and postoperative survey improvement. Results: Two hundred forty-five patients were analyzed. Most were male (66%). Median age and body mass index were 65 and 28.9 kg/m2, respectively. 64.5% of patients were White, and 29.0% were Black. 30.2% had an elevated CRP (≥10 mg/L). 45 (18.4%) patients screened positive for major depressive symptoms on PHQ-8 (≥10 points). Patients with elevated CRP were more likely to have positive preoperative depression screening (odds ratio [OR] 2.66, 95% CI 1.08–6.52, P = .033) but had higher probability of demonstrating meaningful change on PHQ-8 after nephrectomy (OR 3.50, 95% CI 1.04–11.85, P = .044). Conclusion: In nonmetastatic RCC, patients with elevated preoperative CRP had higher scoring for major depressive symptoms on PHQ-8 and were more likely to demonstrate clinical improvement in depressive symptomatology after nephrectomy.

show abstract

Section: Discussionsupporting

confidence: 60%

Section: Introductionmentioning

confidence: 99%

The association of C-reactive protein with major depressive symptoms in nonmetastatic renal cell carcinoma

Nicaise,

Schmeusser,

Biermann

et al. 2023

Journal of Psychosocial Oncology Research &Amp; Practice

View full text Add to dashboard Cite

show abstract

“…Additionally, kidney cancer survivors spend a lot of time sedentary, which is defined as any behavior, including sitting, reclining, or lying down, performed during waking hours. Sedentary behavior is linked to adverse health outcomes for kidney cancer survivors, including decreased physical functioning, increased pain and fatigue, decreased well-being, and reduced QoL (Tabaczynski,et al [16]) Furthermore, sleep disturbances are also one of the symptoms most cited by cancer patients during and after treatment [17,18]. Therefore, better sleep quality and longer sleep duration are associated with positive health and well-being and are fundamental to maintaining QoL during the process.…”

Section: Quality Of Life Of Patients With Crcmentioning

confidence: 99%

"Renal Cell Carcinoma: A Review on Patients’ Quality of Life"

Pereira Soares

2024

BJSTR

View full text Add to dashboard Cite

show abstract

“…19 Furthermore, psychiatric illnesses have been linked to worse clinical outcomes. 20 In response to this multifaceted challenge, we developed a mobile health (mHealth) application specifically tailored to patients with advanced RCC receiving ICI and VEGFR-TKI combination therapies and assessed the acceptance and feasibility of such an intervention. This innovative platform integrates personalized educational resources guiding diagnosis, prognosis, therapy, therapy-related AEs, and quality-of-life reporting tools to holistically support and address patient's needs.…”

Section: Introductionmentioning

confidence: 99%

Feasibility of a Smartphone Application for Education and Symptom Management of Patients With Renal Cell Carcinoma on Combined Tyrosine Kinase and Immune Checkpoint Inhibitors

Roman Souza,

Turner,

Gullapalli

et al. 2024

JCO Clin Cancer Inform

View full text Add to dashboard Cite

PURPOSE Patients with advanced renal cell carcinoma (RCC) face significant challenges, stemming both from the complexities of the disease itself and the adverse effects of treatments. This study evaluated the feasibility and acceptability of a mobile health (mHealth) application tailored for education and symptom management of patients with advanced RCC receiving combined immune checkpoint inhibitor and tyrosine kinase inhibitor (ICI-TKI) therapy. METHODS The primary end points were acceptability and feasibility. Acceptability was defined as the proportion of patients approached who consented to participate, setting a benchmark of at least 50% for this metric. Feasibility was gauged by the completion rate of the intervention among the participants; it required at least 50% of participants to fully complete the intervention and at least 70% to finish half of the administered questionnaires. The secondary end points included knowledge assessment and patient-reported outcomes (PROs). PROs were evaluated using validated instruments. To discern the changes between pre- and post-educational module quiz scores, we used the Wilcoxon signed-rank test. Time-course data of PROs were visualized using line plots and then compared using paired t-tests. RESULTS From November 2022 to July 2023, 20 of 22 (90%) patients approached for the study consented and enrolled. Of the enrolled patients, 60% completed all questionnaires and knowledge assessments at every time point and 75% completed at least half of the surveys and questionnaires. Significant pre/post differences were noted in two of six quizzes in the knowledge assessment. This study population did not experience a significant change in PRO scores after starting therapy. CONCLUSION The mHealth application designed for education and symptom management in patients with advanced RCC undergoing combination ICI-TKI has proven to be both acceptable and feasible, meeting previous research benchmarks.

show abstract

Psychological Distress in Patients Treated for Renal Cell Carcinoma: A Systematic Literature Review

Cited by 4 publications

References 38 publications

The association of C-reactive protein with major depressive symptoms in nonmetastatic renal cell carcinoma

The association of C-reactive protein with major depressive symptoms in nonmetastatic renal cell carcinoma

"Renal Cell Carcinoma: A Review on Patients’ Quality of Life"

Feasibility of a Smartphone Application for Education and Symptom Management of Patients With Renal Cell Carcinoma on Combined Tyrosine Kinase and Immune Checkpoint Inhibitors

Contact Info

Product

Resources

About